您好,欢迎访问中山大学肿瘤防治中心官方网站!
职工邮箱 图书馆 OA系统 医生门户 English
院士风采 首席专家 临床专家 科研学者 客座教授 人才名录
首页
  • 朱孝峰

    职称:实验研究部副主任
    职务:研究员,博士生导师
    专长:肿瘤信号转导途径及靶向肿瘤异常信号转导途径的药物研究
      1970年9月出生,教授,博士生导师。中山大学肿瘤防治中心华南肿瘤学国家重点实验室实验研究部副主任。主要从事肿瘤信号转导与靶向药物研究。2000年在美国乔治城大学癌症中心学习,2007年入选教育部新世纪优秀人才支持计划。广东省肿瘤药理专业委员会主任委员,中国抗癌协会抗癌药物专业委员会委员。《Chin J Cancer》、《Front Pharmacol》、《Advances in Therapy》、《肿瘤防治研究》、《中华肿瘤防治杂志》杂志编委。先后承担国家自然科学基金六项、973计划课题(组长)1项、973计划课题(骨干)1项以及863计划、省市科技项目等多项课题。在国际SCI收录杂志发表论文70余篇,第一作者/通讯作者40余篇,包括Nature Communications, Autophagy, Leukemia, Cancer Research, Oncogene等国际著名杂志,主编人民卫生出版社出版的《信号转导与疾病》和广东科技出版社出版的《肿瘤生物治疗学》专著二部。申请专利九项,三项发明专利已获授权,研究的抗肿瘤新药阿诺宁脂肪乳注射液已转让企业开发。

      1970年9月出生,教授,博士生导师。中山大学肿瘤防治中心华南肿瘤学国家重点实验室实验研究部副主任。主要从事肿瘤信号转导与靶向药物研究。2000年在美国乔治城大学癌症中心学习,2007年入选教育部新世纪优秀人才支持计划。广东省肿瘤药理专业委员会主任委员,中国抗癌协会抗癌药物专业委员会委员。《Chin J Cancer》、《Front Pharmacol》、《Advances in Therapy》、《肿瘤防治研究》、《中华肿瘤防治杂志》杂志编委。先后承担国家自然科学基金六项、973计划课题(组长)1项、973计划课题(骨干)1项以及863计划、省市科技项目等多项课题。在国际SCI收录杂志发表论文70余篇,第一作者/通讯作者40余篇,包括Nature Communications, Autophagy, Leukemia, Cancer Research, Oncogene等国际著名杂志,主编人民卫生出版社出版的《信号转导与疾病》和广东科技出版社出版的《肿瘤生物治疗学》专著二部。申请专利九项,三项发明专利已获授权,研究的抗肿瘤新药阿诺宁脂肪乳注射液已转让企业开发。

    近年发表的主要论文 (*为通讯作者)
      1.Ting Sun, Xuan Li, Peng Zhang, Wen-Dan Chen, Hai-Liang Zhang, Dan-Dan Li, Rong Deng, Xiao-Jun Qian, Lin Jiao, Jiao Ji, Yuan-Tian Li, Rui-Yan Wu, Yan Yu, Gong-Kan Feng, Xiao-Feng Zhu*. Acetylation of Beclin 1 inhibits autphagosome maturation and promotes tumour growth. Nat Commun. 2015; 6: 7215.
      2.Jing-Hong Chen, Peng Zhang, Wen-Dan Chen, Dan-Dan Li, Rong Deng, Xuan Li, Jiao Ji, Gong-Kan Feng, Yi-Xin Zeng, Jian-Wei Jiang*, Xiao-Feng Zhu*. ATM-mediated PTEN phosphorylation promotes PTEN nuclear translocation and autophagy in response to topotecan in cancer cells. Autophagy, 2015; 11(2): 239-52
      3.Yun-Tian Li, Xiao-Jun Qian, Yan Yu, Zhen-Hua Li, Rui-Yan Wu, Jiao Ji, Lin Jiao, Xuan Li, Peng-Fei Kong, Wen-Dan Chen, Gong-Kan Feng, Rong Deng, Xiao-Feng Zhu*. EGFR tyrosine kinase inhibitors promote pro-caspase-8 dimerization that sensitizes cancer cells to DNA-damaging therapy. Oncotarget. 2015 Apr 29. [Epub ahead of print]
      4.Xiao-jun Qian, Yun-tian Li, Yan Yu, Yang Fen, Rong Deng, Jiao Ji, Lin Jiao, Xuan Li, Rui-Yan Wu, Wen-Dan Chen, Gong-Kan Feng, Xiao-Feng Zhu*. Inhibition of DNA Methyltransferase as a Novel Therapeutic Strategy to Overcome Acquired Resistance to Dual PI3K/mTOR Inhibitors. Oncotarget. 2015; 6(7): 5134-46
      5.Juan Qin, Jiao Ji, Rong Deng, Jun Tang, Fen Yang, Gong-Kan Feng, Wen-Dan Chen, Xiao-Qi Wu, Xiao-Jun Qian, Shao-Hua Chang, Ke Ding, Xiao-Feng Zhu*. DC120, a novel AKT inhibitor, preferentially inhibits nasopharyngeal carcinoma cancer stem-like cells by downregulating Sox2 expression. Oncotarget. 2015; 6(9):6944-58
      6.Yang F, Deng R, Qian XJ, Chang SH, Wu XQ, Qin J, Feng GK, Ding K, Zhu XF*. Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer. Cell Death Dis. 2014 Mar 13;5:e1114.
      7.He JH, Liao XL, Wang W, Li DD, Chen WD, Deng R, Yang D, Han ZP, Jiang JW, Zhu XF*. Apogossypolone, a small-molecule inhibitor of Bcl-2, induces radiosensitization of nasopharyngeal carcinoma cells by stimulating autophagy. Int J Oncol, 2014:45(3): 1099-108.
      8.Yang F, Qian XJ, Qin W, Deng R, Wu XQ, Qin J, Feng GK, Zhu XF*. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma.  PLoS One. 2013;8(3):e59879
      9.Xiao-Yue Zhang, Xiao-Qi Wu, Rong Deng, Ting Sun, Gong-Kan Feng, Xiao-Feng Zhu*. Upregulation of sestrin 2 expression via JNK pathway activation contributes to autophagy induction in cancer cells. Cell Signal. 2013 Jan;25(1):150-8
      10.Rong Deng, Fen Yang, Shao-Hua Chang, Jun Tang, Juan Qin, Gong-Kan Feng, Ke Ding, Xiao-Feng Zhu*. DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth. Mol Pharmacol, 2012, 82(2):189-98
      11.Jun Tang, Rong Deng, Rong-Zhen Luo, Guo-Ping Shen, Mo-Yan Cai, Zi-Ming Du, Shang Jiang, Ming-Tian Yang, Jian-Hua Fu, Xiao-Feng Zhu*. Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients. Breast Cancer Res Treat, 2012, 134(2):549-60
      12.Dan-Dan Li, Ting Sun, Xiao-Qi Wu, Shu-Peng Chen, Rong Deng, Shan Jiang, Gong-Kan Feng, Jin-Xuan Pan, Xiao-shi Zhang, Yi-Xin Zeng, Xiao-Feng Zhu*. The Inhibition of Autophagy Sensitises Colon Cancer Cells with Wild-Type p53 but Not Mutant p53 to Topotecan Treatment. PLoS ONE*, 2012, 7(9): e45058. doi:10.1371/journal.pone.0045058
      13.Shan Jiang, Yong Li, Ying-Hui Zhu, Xiao-Qi Wu, Jun Tang, Zheng Li, Gong-Kan Feng, Rong Deng, Dan-Dan Li, Rong-Zhen Luo, Mei-Fang Zhang, Wei Qin, Xin Wang, Wei-Hua Jia, Xiao-Feng Zhu*. Intensive expression of UNC-51-like kinase 1 is a novel biomarker of poor prognosis in patients with esophageal squamous cell carcinoma.  Cancer Science, 2011, 102: 1568–1575
      14.Rong Deng, Jun Tang, Jian-Guo Ma, Shu-Peng Chen, Liang-Ping Xia, Wen-Jun Zhou, Dan-Dan Li, Gong-Kan Feng, Yi-Xin Zeng, Xiao-Feng Zhu*. PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation. Oncogene, 2011, 30: 944-55
      15.Dan-Dan Li, Jin-Feng Guo, Jia-Jia Huang, Lin-Lin Wang, Rong Deng, Jian-Nan Liu, Gong-Kan Feng, Ding-Jun Xiao, Song-Zhi Deng, Xiao-Shi Zhang, Xiao-Feng Zhu*. Rhabdastrellic acid-A induced autophagy-associated cell death through blocking Akt pathway in human cancer cells. PLos One, 2010, 5(8):e12176
      16.Rong Deng, Jun Tang, Bin-Fen Xie, Gong-Kan Feng, Yue-Han Huang, Zong-Chao Liu, Xiao-Feng Zhu*. SYUNZ-16, a new synthesized alkannin derivative, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of AKT/FOXO signal pathway. Int J Cancer, 2010, 127(1):220-9
      17.Wen-Jun Zhou, Rong Deng, Xiao-Yue Zhang, Gong-Kan Feng, Lian-Quan Gu, Xiao-Feng Zhu*. G-quadruplex ligand SYUIQ-5 induces autophagy by telomere damage and TRF2 delocalization in cancer cells. Mol Cancer Ther, 2009, 8:3203-3213
      18.Dan-Dan Li, Lin-Lin Wang, Rong Deng, Jun Tang, Yang Shen, Jin-Feng Guo, Yao Wang, Liang-Ping Xia, Gong-Kan Feng, Quentin Q Liu, Wen-Lin Huang, Yi-Xin Zeng, Xiao-Feng Zhu*. The pivotal role of c-Jun-NH2-terminal kinase-mediated Beclin-1 expression during anticancer agents-induced autophagy in cancer cells. Oncogene, 2009, 28, 886-898.
      19.Rong Deng, Jun Tang, Liang-Ping Xia, Dan-Dan Li, Lin-Lin Wang, Gong-Kan Feng, Yi-Xin Zeng, Xiao-Feng Zhu*. ExcisaninA induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of its signal pathway. Mol Cancer Ther, 2009, 8(4): 873-882.
      20.Hu ZY, Zhu XF(co-first author), Zhong ZD, Sun J, Wang J, Yang D, Zeng YX. ApoG2, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces apoptosis and suppresses tumor growth in nasopharyngeal carcinoma xenografts. Int J Cancer, 2008, 123(10):2418-29
      21.Guan Z, Wang XR, Zhu XF (co-first author), Huang XF, Xu J, Wang LH, Wan XB, Long ZJ, Liu JN, Feng GK, Huang W, Zeng YX, Chen FJ, Liu Q. Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. Cancer Res, 2007;67(21):10436-44
      22.Yu-Ping Mei, Jun-Min Zhou, Yi Wang, He Huang, Rong Deng, Gong-Kan Feng, Yi-Xin Zeng, Xiao-Feng Zhu*. Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells. Cell Cycle, 2007, 6(11): 1379-1385.
      23.Jian-nan Liu, Rong Deng, Jin-Feng Guo, Jun-Min Zhou, Gong-Kan Feng, Zhi-Shu Huang, Lian-Quan Gu, Yi-Xin Zeng, Xiao-Feng Zhu*.  Inhibition of myc promoter and telomerase activity and induction of delayed apoptosis by SYUIQ-5, a novel G-quadruplex interactive agent in leukemia cells. Leukemia, 2007, 21(6), 1300-1302
      24.Rong Deng, Wenming Li, Zhong Guan, Jun-Min Zhou, Yi Wang, Yu-Ping Mei, Ming-Tao Li, Gong-Kan Feng, Wenlin Huang, Zong-Chao Liu, Yifan Han, Yi-Xin Zeng and Xiao-Feng Zhu*. Acetylcholinesterase expression mediated by c-Jun-NH2-terminal kinase pathway during anticancer drug-induced apoptosis.  Oncogene, 2006, 25(53):7070-7
      25.Jun-Min Zhou, Xiao-Feng Zhu*, Yu-Jin Lu, Rong Deng, Zhi-Shu Huang, Yu-Ping Mei, Yi Wang, Wenlin Huang, Zong-Chao Liu, Lian-Quan Gu and Yin-Xin Zeng. Senescence and telomere shortening induced by novel potent G-quadruplex interactive agents, quindoline derivatives, in human cancer cell lines. Oncogene, 2006, 25, 503-511
      26.Xiao-Feng Zhu*, Jing-Song Wang, Li-Ling Cai, Yi-Xin Zeng and Dajun Yang. SUCI02 inhibits the erbB-2 tyrosine kinase receptor signaling pathway and arrests the cell cycle in G phase in breast cancer cells. Cancer Science, 2006, 97(1): 84-89
      27.Yu-Ping Mei, Xiao-Feng Zhu*, Jun-Min Zhou, He Huang, Rong Deng, Yi-Xin Zeng. siRNA targeting LMP1-induced apoptosis in EBV-positive lymphoma cells is associated with inhibition of telomerase activity and expression. Cancer Letters, 2006, 232, 189-198
      28.Xiao-Feng Zhu, Bin-Fen Xie, Jun-Min Zhou, Gong-Kan Feng, Zong-Chao Liu, Xiao-Yi Wei, Feng-Xian Zhang, Mei-Fang Liu and Yi-Xin Zeng. Blockade of VEGF receptor signal pathway and antitumor activity of ON-III, a component from Chinese herbal medicine. Mol Pharmacol, 2005, 67(5):1444-1450.
      29.Xiao-Feng Zhu, Zong-Chao Liu, Bin-Fen Xie, Yi-Xin Zeng. Ceramide induces cell cycle arrest and upregulates p27kip in nasopharyngeal carcinoma cells. Cancer Letters, 2003, 193(2):149-155.
      30.Xiao-Feng Zhu, Zong-Chao Liu, Bin-Fen Xie, Zhi-Min Li, Gong-Kan Feng, Dajun Yang, Yi-Xin Zeng. EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cell line CNE2.  Cancer Letters, 2001, 169 (1): 27-32.

    主编的专著
      1. 《信号转导与疾病》,2012年5月人民卫生出版社出版,(黄文林,朱孝峰主编)
      2. 《肿瘤生物治疗学》,2005,12,广东科技出版社,(姜文奇,张晓实,朱孝峰,李志铭主编)
      3. 《肿瘤分子靶向治疗》,2009,5,人民卫生出版社,(朱孝峰,副主编)
      4. 《黑色素瘤基础与临床》,2010,11,人民卫生出版社,(朱孝峰,副主编)
        5. 《肿瘤360》,2014,10,凤凰科学技术出版社,(朱孝峰,副主编)

    申请的专利
       1.5-噻唑酰胺类化合物及生物学应用,2010.10,中国,2010102651155。
      2.一种抗肿瘤化合物Chondrosterin J 及其制备方法与运用, 2013.12 , 中国,201310692093.4。
      3.Hirsutanols A 在制备抗肿瘤药物中的应用,2009.10,中国,ZL200910037541.0。
      4.紫草萘醌类衍生物及其在制备抗癌药物中的应用。中国专利号:ZL02114973.9
      5.脂肪氨基取代喹啉衍生物及其制备方法和制药用途。中国专利号:ZL200310112457.3;国际专利申请号:PCT/CN2004/000175。
      6.Houttuyninum compositions and methods for inhibiting the activity of erbB-2 based thereon. 国际专利申请号:PCT/US01/43123。
      7.碘化-3,3’-二乙基-9-甲基-硫杂羰花青的抗肿瘤新用途。中国专利申请号:02134263.6。
      8.人表皮生长因子受体2酪氨酸激酶抑制剂。 中国专利申请号:200410052496.3
      9.一种查尔酮肟及其组合物、制备方法和应用。中国专利号:ZL200510101717.6

                更新时间:2015.7.1

访客通道
员工通道
关注肿瘤医院